Search
Neurocrine Biosciences Inc
NBIXAdd to Watchlist
159.760USD
-6.290-3.79%
Close 11-05 16:00（ET）
16.24BMarket Cap
23.87P/E TTM
Neurocrine Biosciences Inc (NBIX) Stock Price Target & Forecast
Analyst Rating
Based on 31 analysts giving stock ratings to Neurocrine Biosciences Inc in the past month.
Buy
13 Strong Buy
14 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
206.620USD+41.42%
NBIX Analyst Recommendation Trends
In the current month, NBIX has received 14 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the last month is 206.620.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
13
13
12
12
12
11
11
11
14
14
14
15
14
14
15
15
4
4
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
31
30
31
30
29
30
30
NBIX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
AbbVie Inc
ABBV
8
18
6
0
0
32
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Regeneron Pharmaceuticals Inc
REGN
6
15
9
0
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, NBIX EPS is projected to reach 1.988 in FY2026Q4, following reported EPS of 2.032 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
1.17
1.34
1.91
1.99
2.15
Actual
1.97
1.43
2.03
--
--
Surprise
+67.68%
+6.51%
+6.45%
--
--
FAQs
What is Neurocrine Biosciences Inc's expected revenue for the next quarter?
Neurocrine Biosciences Inc's expected revenue is 1.09B.
What is Neurocrine Biosciences Inc's price target?
Analysts forecast that Neurocrine Biosciences Inc's price target is USD 206.62, with the highest forecast at USD 253.00 and the lowest forecast at USD 165.00.
How have Neurocrine Biosciences IncNBIX's recent earnings per share performed?
The market expectation was USD 2.03, while Neurocrine Biosciences IncNBIX's earnings per share (EPS) for the previous quarter was USD 1.43. EPS for the next quarter is expected at USD 1.99.
What is the analyst rating for Neurocrine Biosciences Inc?
Based on the ratings of Neurocrine Biosciences Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.